One of the other oral GLP-1s on the horizon, Pfizers danuglipron pill, led to a similar weight loss as injectable semaglutide according to results recently released from Phase 2 clinical trials
Strong clinical trial results, widespread physician adoption, and high patient preference for oral administration enhance its market leadership
It should not be used in neonates, pregnant women, certain medications, or for intrathecal injection
The patient demographic predominantly consisted of individuals aged between 18 and 64 years, accounting for 53.57%77.42% of the sample, while the proportion of minors ranged from 8.57% to 21.34%
GLP-1 receptor agonists reduce all-cause mortality and major adverse cardiovascular events (MACE) by approximately 1213% in high-risk populations, as detailed in this 2025 review of cardiovascular effects of GLP-1 receptor agonists on PubMed
Cagrilintide is a long-acting amylin analogue with dual amylin and calcitonin receptor activity, whereas semaglutide is a once-weekly GLP-1 receptor agonist with robust anti-hyperglycemic and appetite-suppressing effects